65,437 trials
Renal Insufficiency
Primary: Total Daily Area Under the Plasma Concentration-time Profile From Time 0 to 24 Hours at Steady-state (AUC0-24,ss) of Aztreonam (ATM) — 922.9; 733.5 Microgram*hour per…
Pelvic Organ Prolapse · Prolapse
Primary: The Ability of the Study Device to be Retained During Valsalva Compared to the Ability of the Subject's Current Pessary to be Retained During Valsalva (Change in…
Healthy
Primary: Area Under Plasma Concentration-time Curve From Time Zero to Last Sampling Time (Tlast) at Which the Concentration is at or Above the Lower Limit of Quantification…
Healthy
Primary: Maximum Observed Plasma Concentration (Cmax) on Day 1 & 4 of Aztreonam — 69.44; 79.66 micrograms per milliliter (ug/mL)
Glabellar Lines
Primary: Percentage of Participants With ≥ 2-grade Improvement From Baseline on the FWS According to Investigator's Assessment at Any Postintervention Timepoint Through Day 7…
Schizophrenia
Primary: Change in Precuneus Functional Activation — 0.0329; 0.067; -0.010 Beta coefficient change (Target vs Foil) — p=0.32
Donor Site Complication
Primary: Number of Participants With Treatment-related AEs and SAEs (Including Infections and Bleeding) — 0; 0; 0; 0 Participants
Asthma
Primary: Maximum Observed Mometasone Furoate Plasma Concentration (Cmax) — 51.9; 53.5 pg/mL
Hepatocellular Carcinoma (HCC)
Primary: Objective Response Rate (ORR) Assessed by Independent Review Committee (IRC) — 12.9 Percentage of participants — p=0.0001
Adult Myelodysplastic Syndrome · Anemia · Chronic Myelomonocytic Leukemia
Primary: Number of Patients Demonstrating Overall Hematologic Improvement (HI) — 6; 5; 7 Participants
Temporomandibular Joint Disorders
Primary: Pressure Pain Threshold — 4.56; 5.27; 3.81; 4.51 lbf — p=.99
Painful Bladder Syndrome · Interstitial Cystitis
Primary: Percentage of Responders to Treatment — 25 Participants
SARS-CoV-2 Infection
Primary: Efficacy of Moderna COVID-19 Vaccine Against SARS-CoV-2 Infection — 12.2; 31.8; 89.6 events per 100 person years
Hidradenitis Suppurativa · Acne Inversa · Suppurative Hidradenitis
Primary: Percentage of Participants Who Achieved Hidradenitis Suppurativa Clinical Response (HiSCR) at Week 12 — 46.2; 44.0; 54.9 Percentage of participants
Sunburn, Erythema · Sun Protection
Primary: Acceptability of Wearing UV Sensor and Receiving Text Messages — 22; 39.1; 40.1; 40.6 score on a scale — p=<0.01